Effects of Breastfeeding on Maternal Plasma Ghrelin and Peptide Tyrosine Tyrosine (PYY) Levels
NCT ID: NCT00831818
Last Updated: 2011-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2008-07-31
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hormonal Regulation of Postpartum Weight and Presence of Gut Peptides in Human Milk
NCT01514539
Does Breastfeeding Lower Blood Pressure in Postpartum Hypertensive Patients
NCT02574494
Effect of Breastfeeding on Lipid Profile and Cardiovascular Risk Markers in Women With Familial Hypercholesterolemia
NCT05367310
Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial
NCT01465022
Recombinant Human Prolactin for Lactation Induction
NCT00181623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
While the physiological and pathological control of appetite has attracted much attention in these times of increasing prevalence of obesity, nothing is known on the regulation of gut peptides during breastfeeding. Concerns that long-term weight retention after pregnancy contributes to increasing rates of obesity underscore the importance of understanding postpartum energy utilization (Mokdad et al). The 6 months following delivery of the baby are associated with a significant decrease of maternal fat mass. Fat mobilisation appears to be physiologic and gradual, even when food is readily available. Trunk fat and thigh fat are the primary energy depots mobilized to support lactation (Butte et Hopkinson). Several studies have revealed that breastfeeding facilitates post-partum weight loss (8,10). Nevertheless, it was shown that lactating women loose central and peripheral fat less rapidly then nonlactating women (Wosje et Kalkwarf). Prolonged breastfeeding has been shown to reduce the risk of developing obesity in the offspring (Cripps et al), and ghrelin has been suggested as a hormonal link between the duration of breastfeeding and body weight development (Fak et al).
The endocrinology of lactating women consists in increased amounts of prolactin and oxytocin, needed for milk production and release respectively. Very little is known on the relationship between these hormones and the appetite-modulating gut peptides. Intravenous ghrelin activates the hypothalamic-hypophysis-adrenal axis in humans and also increases prolactin release in healthy humans (Aimaretti et al). Intraventricular ghrelin administration increases intrahypothalamic oxytocin production in rats (Olszewski et al).
We recently found that continuous intravenous injection of Oxytocin decreases plasma ghrelin concentrations in healthy men (own recent and not yet published data). It is thought that increased circulating Prolactin stimulates appetite in lactating women, but there are no data on the effects of Prolactin on appetite-modulating gut hormones (Grattan). With the proposed study we aim to check the relevance of these findings in normal physiology and to study the breastfeeding-induced changes in circulating ghrelin and PYY concentrations in lactating mothers.
Setting Clinical Trial Unit of the Division of Endocrinology and Metabolism, Department of Internal Medicine III, AKH, Waehringer Gürtel 18-20, A-1090, Vienna.
Study Subjects Study group: Ten mothers of healthy infants who breastfeed on demand. Control group: Ten mothers of healthy infants who do not breastfeed.
Study Protocol
Breastfeeding group:
The study will start at ca. 10h00-12h00 and the women will be fasting since ca. 4 hours. There will be no restriction of water-intake before and throughout the study. An intravenous cannula will be inserted in the antecubital vein of one arm for blood withdrawal. The arm not needed for carrying the baby during breastfeeding will be used (e.g. if the baby is due to drink on the right breast, the intravenous cannula will be put on the left arm, und vice versa). In any case, a support cushion will be used for breastfeeding. The subjects will rest for ca. 30 minutes. Then, a basal blood withdrawal will be performed.
When the mother decides to breastfeed the baby on demand, blood will be withdrawn immediately before breastfeeding (time 0) and then at time points 15, 30 and 60 minutes. The duration of breastfeeding will be noted. 9 ml blood will be withdrawn in an EDTA-containing vacutainer at each timepoint (total 45 ml during the whole study). Ca 100µl will be separated into a cap for the online measuring of glucose, while the rest will be immediately cooled on ice and centrifuged within 30 minutes. Plasma will be aliquoted in 3 cryotubes, 2 of which will be frozen in -80°C and the third in -20°C.
Control Group:
The study will start at ca. 10h00-12h00 and the women will be fasting since ca. 4 hours. There will be no restriction of water-intake before and throughout the study. An intravenous cannula will be inserted in the antecubital vein of one arm for blood withdrawal. The subjects will rest for ca. 30 minutes. Then, a basal blood withdrawal will be performed, thereafter 4 times halfhourly.
Statistical analysis The sample number (10 breast-feeding and 10 not-breastfeeding mothers) can detect with 80% power a difference of 18% between ghrelin values after breastfeeding (α=0.05, β=0.2). Statistics will be performed using the SPSS release 12.0.1 software. Changes in hormone concentrations will be compared with repeated measures ANOVA. A possible association between parameters will be tested using linear regression analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Mothers of healthy infants who breastfeed on demand
No interventions assigned to this group
2
Mothers of healthy infants who do not breastfeed
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* healthy mothers (with normal BMI) fully breastfeeding their infants (aged 3 to 6 months) on demand
* past normal pregnancy
Group 2:
* healthy mothers (with normal BMI) that do not breastfeed their infants (aged 3 to 6 months)
* past normal pregnancy
Exclusion Criteria
* cardiocirculatory, kidney or liver disease of the mother
* infants having growth problems or any other current disease
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Clodi, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Endocrinology and Metabolism, Medical University of Vienna
Anton Luger, MD
Role: STUDY_CHAIR
Division of Endocrinology and Metabolism, Medical University of Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AKH, Medical University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Breastfeeding_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.